US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

QiYu Hand Sanitizer

Reason Subpotent

Native Promotions, INC D-0793-2021
Class II · Moderate risk Completed

Compounded Lyophilized AOD-9604

Reason Lack of Assurance of Sterility

Innoveix Pharmaceuticals Inc D-0693-2021
Class II · Moderate risk Terminated

Sulfamethoxazole and Trimethoprim Tablets

Reason Presence of Foreign Substance- Potential of metal contamination.

Aurobindo Pharma USA Inc. NDC 65862-420-05 D-0719-2021
Class II · Moderate risk Terminated

NIFEdipine EXTENDED-RELEASE TABLETS

Reason Failed Dissolution Specification: Out of specification for dissolution during routine stability testing.

The Harvard Drug Group NDC 0904-7080-61 D-0652-2021
Class II · Moderate risk Terminated

Global Hand Sanitizer with moisturizer

Reason CGMP Deviations: Does not meet monograph for denaturant.

Cascade Kelly Holdings LLC NDC 80253-001-02 D-0698-2021
Class II · Moderate risk Terminated

Global Hand Sanitizer with moisturizer

Reason CGMP Deviations: Does not meet monograph for denaturant.

Cascade Kelly Holdings LLC NDC 80253-001-01 D-0697-2021
Class II · Moderate risk Terminated

Zyprexa Intramuscular

Reason cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

Eli Lilly & Company NDC 0002-7597-01 D-0720-2021
Class II · Moderate risk Terminated

Xylocaine-MPF with Epinephrine 1:200

Reason Low out of specification results for epinephrine assay.

Fresenius Kabi USA LLC NDC 63323-487-07 D-0651-2021
Class II · Moderate risk Ongoing

QiYu Hand Sanitizer

Reason Subpotent

Hoyu(us) Logistics INC D-0643-2021
Class II · Moderate risk Terminated

Acetaminophen 325 mg tablets

Reason cGMP deviations: Discolored acetaminophen

Spirit Pharmaceuticals NDC 79903-052-10 D-0729-2021
Class II · Moderate risk Ongoing

Chantix

Reason CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

Pfizer Inc. NDC 0069-0469-56 D-0701-2021
Class II · Moderate risk Ongoing

Chantix

Reason CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

Pfizer Inc. NDC 0069-0471-03 D-0700-2021